If the iPSCs you would like to access are currently listed as unavailable or
you would like information on local partners in USA, Australia, New Zealand or Japan who can support order and delivery,
please get in touch via
Contact@EBiSC.org.
PFIZi016-A
OD005-s9
iPSC line
Timepoint: 48hr post thaw
Magnification: x4
Magnification: x4
Timepoint: 48hr post thaw
Magnification: x10
Magnification: x10
Timepoint: Confluency
Magnification: x4
Magnification: x4
Timepoint: Confluency
Magnification: x10
Magnification: x10
A CLIP contains information about an iPSC line including any
specific third party obligations relating to, for example,
licensing obligations or the donor consent which affect the
use of the iPSC line.
The EBiSC Access and Use Agreement must be completed along with an individual
Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org
for countersignature. The EAUA must be fully signed before proceeding with your order.
A batch specific Certificate of Analysis will be available to
download once you receive your EBiSC iPSC line.
General#
iPSC Line |
|
| hPSCreg name | PFIZi016-A |
| Alternative name(s) |
OD005-s9
|
| iPSC line type | Human induced pluripotent stem cell (hiPSC) |
| Similar iPSC lines |
|
Provider |
|
| Depositor | Pfizer Limited - Pfizer (PFIZ) |
| Distributors |
EBiSC
|
External iPSC Databases |
|
| hPSCreg | PFIZi016-A |
| BioSamples | SAMEA4454950 |
| Cellosaurus | CVCL_IJ03 |
| Wikidata | Q54947271 |
General iPSC Information |
|
| Publications | View all related publications on hPSCreg (1) |
| This EBiSC iPSC line can be used for: |
Yes
Research use: allowed
Clinical use: no
Commercial use: no
|
Donor Information#
General Donor Information |
|
| Sex | female |
| Age of donor (at collection) | 15-19 |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Disease associated phenotypes |
|
External Databases (Donor) |
|
| BioSamples | SAMEA4454949 |
iPSC Derivation#
General |
|
| Source cell type |
A nucleated precursor of an erythrocyte that lacks hematopoietic lineage markers.
Synonyms
|
| Source cell type (free text) | Blood - PBMC erythroblasts |
| Age of donor (at collection) | 15-19 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
iPSC Culture Conditions#
Latest released batch |
|
| Culture medium | Essential 8 |
| Passage method | EDTA |
| Surface coating | Matrigel / Geltrex |
| O2 concentration | 21 |
| CO2 concentration | 5 |
| Temperature | 37 |
The following are the depositor culture conditions, they do not refer to any specific batch.
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 21 % |
| CO2 Concentration | 5 % |
| Medium |
Essential 8™
|
iPSC Characterisation#
Analysis of undifferentiated iPSCs
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|
||||
| SSEA-1 |
No |
|
||||
| SSEA-4 |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
|
Self-renewal
Negative
Endoderm
Unknown
Mesoderm
Unknown
Ectoderm score
Unknown
Scorecard
Differentiation Potency
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Sterility |
|
| Inoculation for microbiological growth | No Contaminants Detected |
| Mycoplasma | Not Detected |
| Viability | Viable post-cryopreservation |
Genotyping#
Karyotyping (iPSC Line) |
|
| Has the iPSC line karyotype been analysed? |
Yes
No autosomal or sex chromosome aneuplodies were detected
Passage number: 20
Karyotyping method:
BoBs
|
Other Genotyping (iPSC Line) |
|